News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
65,603 Results
Type
Article (4690)
Company Profile (16)
Press Release (60897)
Section
Business (23833)
Career Advice (107)
Deals (4136)
Drug Delivery (59)
Drug Development (5556)
Employer Resources (13)
FDA (1237)
Job Trends (1286)
News (33718)
Policy (1904)
Tag
Academia (259)
Alliances (5811)
Alzheimer's disease (145)
Approvals (1222)
Artificial intelligence (47)
Bankruptcy (40)
Best Places to Work (892)
Cancer (136)
Cardiovascular disease (33)
Career advice (86)
Cell therapy (42)
Clinical research (4224)
Collaboration (92)
COVID-19 (187)
C-suite (32)
Data (139)
Diabetes (87)
Diagnostics (682)
Drug pricing (54)
Drug shortages (20)
Earnings (5104)
Events (6229)
Executive appointments (109)
FDA (1318)
Funding (313)
Gene therapy (34)
GLP-1 (437)
Government (265)
Healthcare (1588)
Infectious disease (195)
IPO (1924)
IRA (20)
Job creations (411)
Job search strategy (83)
Layoffs (51)
Legal (374)
Lung cancer (20)
Manufacturing (63)
MASH (19)
Medical device (1619)
Medtech (1621)
Mergers & acquisitions (2271)
Metabolic disorders (307)
Neuroscience (186)
NextGen: Class of 2025 (1041)
Non-profit (325)
Northern California (231)
Obesity (216)
Opinion (61)
People (9425)
Phase I (1349)
Phase II (1916)
Phase III (1320)
Pipeline (64)
Podcasts (33)
Policy (37)
Postmarket research (148)
Preclinical (675)
Radiopharmaceuticals (26)
Rare diseases (45)
Real estate (661)
Regulatory (1403)
Research institute (199)
Resumes & cover letters (19)
Series A (87)
Series B (59)
Southern California (161)
Startups (2194)
Supply chain (22)
The Weekly (30)
United States (1557)
Vaccines (36)
Venture capitalists (30)
Weight loss (209)
Date
Today (6)
Last 7 days (64)
Last 30 days (250)
Last 365 days (3695)
2025 (599)
2024 (3808)
2023 (3721)
2022 (6363)
2021 (5632)
2020 (5380)
2019 (4907)
2018 (3927)
2017 (3660)
2016 (2980)
2015 (3324)
2014 (2450)
2013 (2027)
2012 (2186)
2011 (2410)
2010 (2472)
Location
Africa (80)
Asia (4490)
Australia (632)
California (494)
Canada (426)
China (50)
Connecticut (30)
Europe (10566)
Florida (42)
Illinois (42)
Indiana (29)
Japan (17)
Maryland (53)
Massachusetts (319)
Michigan (23)
Minnesota (18)
New Jersey (100)
New York (101)
North Carolina (58)
Northern California (231)
Ohio (25)
Pennsylvania (62)
South America (112)
Southern California (161)
Texas (64)
Washington State (30)
65,603 Results for "novo ventures".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s
blockbuster
Hemlibra.
February 7, 2025
·
2 min read
·
Dan Samorodnitsky
Obesity
Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss
The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% weight reduction.
January 24, 2025
·
2 min read
·
Tristan Manalac
GLP-1
Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.
February 12, 2025
·
2 min read
·
Annalee Armstrong
Layoffs
Novo Partner Omega Waves Bankruptcy Flag from Sinking Ship
Just over a year after striking an obesity deal with Novo Nordisk, an SEC filing shows Flagship Pioneering spinout Omega Therapeutics is days away from bankruptcy and will lay off up to 17 employees.
February 4, 2025
·
1 min read
·
Kate Goodwin
GLP-1
EMA to Investigate Eye Risk for Novo’s Ozempic: Reuters
Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have strengthened the link between Novo Nordisk’s blockbuster GLP-1 and a rare eye disease.
December 18, 2024
·
2 min read
·
Annalee Armstrong
Legal
Novo Seeks $830M in Fraud Case Against Singaporean Biotech Over Kidney Drug
Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a judge seems to agree.
February 18, 2025
·
1 min read
·
Annalee Armstrong
Earnings
Despite Doubled Wegovy Sales, Novo Executives Confront Analysts’ Insatiable Appetite
Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.
February 5, 2025
·
2 min read
·
Annalee Armstrong
Diabetes
Novo Launches Citizen Petition to Block Compounded Victoza
In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, the type 2 diabetes injection it sells as Victoza.
January 6, 2025
·
2 min read
·
Tristan Manalac
IRA
With Wegovy, Ozempic on the Line, Novo Asks Court to Speed Up IRA Complaint
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the second round of the IRA drug price negotiation program, even as the pharma challenges the program.
January 29, 2025
·
1 min read
·
Tristan Manalac
GLP-1
Novo’s CagriSema Blunder Underscores Sky-High Investor Expectations for Weight Loss Drugs
Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 combo didn’t hit that mark, investors reeled.
December 20, 2024
·
3 min read
·
Annalee Armstrong
1 of 6,561
Next
